Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has provided an announcement.
CSL Limited has announced an update on its ongoing on-market buy-back program, revealing that a total of 1,983,576 securities have been bought back prior to the previous day, with an additional 48,811 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting the company’s confidence in its financial health and future prospects.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, primarily focusing on the development and delivery of innovative medicines and vaccines. The company is known for its contributions to the healthcare sector, particularly in the areas of immunology, hematology, and influenza vaccines.
YTD Price Performance: -34.15%
Average Trading Volume: 1,378,407
Technical Sentiment Signal: Sell
Current Market Cap: A$88.21B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.